AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) announced on September 21, 2026, the launch of Quantum Soma, a new project aimed at developing a contactless quantum biosensing platform. The initiative pairs Dynex Quantum Technologies AG's NV-diamond quantum sensing hardware with AIML's proprietary MaxYield™ signal-intelligence platform. The company simultaneously entered a non-binding purchase order with Dynex for up to 2,000 quantum sensors, representing a potential maximum value of CHF 5,000,000 (approximately CAD$8,484,500), with no minimum purchase obligation.

Key Points

  • AI/ML Innovations Inc. (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) announced the Quantum Soma initiative on September 21, 2026
  • A non-binding purchase order covers up to 2,000 Dynex Single Zone NV-Diamond quantum sensors at CHF 2,500 per unit (approximately CAD$4,242 per unit)
  • Dynex is expected to deliver a combined MaxYield™–sensor prototype within approximately nine months; AIML retains sole discretion over prototype acceptance
  • Investors may be watching for prototype results and any decision by AIML to begin drawing down sensor units under the purchase order

Quantum Soma's Contactless Biosensing Architecture

Quantum Soma is designed to read the body's magnetic signatures at a distance, initially targeting cardiac magnetic signals. The platform intends to combine Dynex's NV-diamond sensors — which use nitrogen-vacancy centres in diamond to detect magnetic fields at room temperature without cryogenic cooling — with a modified version of MaxYield™, AIML's AI-based signal-processing engine developed by its wholly owned subsidiary NeuralCloud Solutions Inc. AIML stated the platform may eventually extend its roadmap to include brain, breath, and motion signals, though the initial focus remains on the heart.

Non-Binding Purchase Order Structure and Financial Terms

The purchase order, effective September 21, 2026, is structured as a drawdown arrangement allowing AIML to place unit orders at its discretion, with payment due upon delivery and acceptance. AIML is not obligated to purchase any units and faces no minimum payments, deposits, development fees, or cancellation penalties under the arrangement. At full utilisation, the order would represent CHF 5,000,000 (approximately CAD$8,484,500). Dynex retains all rights to its pre-existing NV-diamond technology, while AIML retains ownership of the MaxYield™ intellectual property regardless of prototype outcome.

MaxYield™ Signal Intelligence as the Core Processing Layer

Originally developed for ECG analysis, MaxYield™ is being adapted within Quantum Soma to process magnetic-field outputs generated by Dynex's quantum sensor. AIML's release states the platform is designed to identify, clean, and deconvolute physiological signals from environmental and biological noise — a challenge the company describes as central to making highly sensitive quantum sensing practically useful in health applications. There are no formal pre-defined acceptance or validation criteria for the prototype phase; AIML retains sole discretion to assess whether performance meets its expectations.

Regulatory Status and Development Stage Cautions

AIML disclosed that Quantum Soma is in development and has not received regulatory clearance or approval for clinical or diagnostic use. Any future clinical or diagnostic application would be subject to applicable regulatory requirements, validation, and clearance or approval in relevant jurisdictions. The company stated its initial objective is to validate whether the combined quantum hardware and signal-intelligence system can detect cardiac magnetic signatures with sufficient fidelity to support future product development. The immediate share price impact was not clear from available public information.